Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774472 | 0.83 | RXRA (0.50) | NR4A2NR4A1NR4A3PTGS1ABCC4 | |
| SCHEMBL5773585 | 0.81 | ALDH1A1 (0.54) | NR4A2NR4A1NR4A3PTGS1ABCC4 | |
| SCHEMBL5774948 | 0.81 | FFAR1 (0.51) | NR4A2NR4A1NR4A3PTGS1ABCC4 | |
| SCHEMBL5772173 | 0.80 | TDO2 (0.55) | NR4A2TSHRGAATDO2KDM4E | |
| SCHEMBL5770831 | 0.78 | NR4A2 (0.52) | NR4A2NR4A1NR4A3PTGS1ABCC4 | |
| SCHEMBL5775970 | 0.77 | TDO2 (0.51) | TDO2KDM4EALDH1A1PTPN1MMP3 | |
| SCHEMBL1796231 | 0.77 | TDO2 (0.42) | NR4A2LMNATDO2ALDH1A1PTPN1 | |
| SCHEMBL5776248 | 0.75 | TDO2 (0.45) | NR4A2TDO2ALDH1A1PTPN1RXRA | |
| SCHEMBL5773847 | 0.74 | CCNC (0.47) | NR4A2PTGS1TSHRGAAKDM4E | |
| SCHEMBL5776861 | 0.73 | PPARA (0.48) | NR4A2NR4A1NR4A3PTGS1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | claimed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | claimed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | claimed |
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | NR4A2 698/4885NR4A1 429/4885NR4A3 152/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | NR4A2 953/4885NR4A1 282/4885NR4A3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.